Local/systemic reactogenicity was assessed the day of vaccination and for 6days thereafter

Local/systemic reactogenicity was assessed the day of vaccination and for 6days thereafter. Top1 inhibitor 1 third dose, and 45 received a fourth dose of NVX-CoV2373. The incidence of local/systemic reactogenicity events increased after the first three doses of NVX-CoV2373 and leveled off after dose 4. Unsolicited AEs were reported in 9 % of participants after dose 4 (none of which were severe or serious). Anti-rS IgG levels and neutralization antibody titers increased following booster doses to a level approximately four-fold higher than that observed after the primary series, with a progressively narrowed gap in response between the ancestral strain and Omicron BA.5. A fourth dose of NVX-CoV2373 enhanced immunogenicity for ancestral and variant SARS-CoV-2 strains without increasing reactogenicity, indicating that updates to the vaccine composition may not be currently warranted. Keywords:Booster, COVID-19, Vaccine immunogenicity, Vaccine safety, SARS-CoV-2 vaccine, NVX-CoV2373 == 1. Introduction == The emergence Top1 inhibitor 1 and rapid propagation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, in particular the Omicron sublineages, which have mutations that increase viral transmissibility and enhance the viruses’ ability to evade vaccine immunity[1],[2], can significantly reduce the efficacy of approved vaccines. The U.S. Food and Drug Administration (FDA) has recommended the development of variant-specific vaccines for the 20222023 winter[3], although some have countered that any additional protection provided by the Omicron-specific vaccines may be minimal[4],[5]. The degree to which immunity induced by SARS-CoV-2 ancestral strain-based vaccines is effective against the Omicron Top1 inhibitor 1 sublineages depends, partly, on the extent that the vaccine is able to induce broadly cross-reactive antibodies. The NVX-CoV2373 vaccine may be able to preferentially induce these antibodies because of its composition. The vaccine consists of full-length, pre-fusion recombinant spike (S) protein trimers with epitopes conserved across variants. In addition, the vaccine is co-formulated with a saponin-based Matrix-M adjuvant (Novavax, Gaithersburg, MD). Similar saponin-based adjuvants have demonstrated the ability to enhance antibody avidity, affinity maturation, and epitope spreading, which may drive recognition of conserved, more immunologically cryptic but broadly neutralizing epitopes[6]. For example, the ISCOMATRIX adjuvant Rabbit polyclonal to HER2.This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases.This protein has no ligand binding domain of its own and therefore cannot bind growth factors.However, it does bind tightly to other ligand-boun promotes epitope spreading and antibody affinity maturation of a pandemic influenza A (H7N9) virus-like particle vaccine which correlates with virus neutralization in humans[6]. In the context of seasonal influenza, a hemagglutinin (HA) nanoparticle Matrix-Madjuvanted vaccine was shown to induce polyclonal antibodies in humans that mimic broadly neutralizing monoclonal antibodies that recognize two conserved regions of the head domain, namely the receptor binding site and the vestigial esterase subdomain. The findings raised the potential for an adjuvanted HA subunit vaccine to induce broadly protective immunity[7]. Clinical and ferret studies Top1 inhibitor 1 using a recombinant full-length HA in a nanoparticle with Matrix-M adjuvant, confirmed that the H3N2 component of the vaccine-induced broadly cross-reacting antibodies against the past, current, and forward-drifted H3N2 strains covering multiple years[8],[9]. Humans are universally primed to influenza, and as this is gradually also becoming the case for SARS-CoV-2, we speculated that repetitive boosting with an ancestral recombinant spike (rS) nanoparticle vaccine with Matrix-M adjuvant, might similarly induce broadly neutralizing antibodies that recognize the drift variants. In two phase III, randomized, placebo-controlled clinical trials of healthy adult participants who received two doses of NVX-CoV2373, vaccine efficacy of 89.7 % (95 % confidence interval [CI]: 80.2 to 94.6) and.